ADA

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

ADA: Safety data offset efficacy for survodutide

New data with Zealand/Boehringer's survodutide reinforce its metabolic benefits, but a high discontinuation rate has raised concerns.

News

ADA: Vertex closer to weaning type 1 diabetics off insulin

A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.

News

ADA: Lilly makes its case for oral GLP-1 orforglipron

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

News

ADA: Novo continues effort to rehabilitate CagriSema

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Cholesterol drug could find new role in diabetic eye disease

A decades-old drug used to lower cholesterol levels in the blood has been shown to reduce the progression of vision-robbing retinopathy in people with diabetes.

ADA: Lilly's weight-loss reveal, and wannabes display wares

ADA: Safety data offset efficacy for survodutide

ADA: Vertex closer to weaning type 1 diabetics off insulin

ADA: Lilly makes its case for oral GLP-1 orforglipron

ADA: Novo continues effort to rehabilitate CagriSema

Cholesterol drug could find new role in diabetic eye disease

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

Discover a new era of healthcare panel engagement: Grounded ...

ADA

Editor's Picks